Usually used in combination with Ledispavir in the treatment of hepatitis C. Since the last update we have not found published data on its excretion in breast milk. Its pharmacokinetic data (moderately elevated molecular weight, good percentage of protein binding and very short half-life) impedes its passage to breast milk in significant amounts, so although there is disagreement (Thompson 2016), some authors consider that treatment with sofosbuvir, alone or in combination with ledipasvir is not contraindicated during breastfeeding (Spera 2016). See below the information of these related products: